300584 Nanjing Hicin Pharmaceutical
- 16.72
- -0.30-1.76%
Nanjing Hicin Pharmaceutical News
Haichen Pharmaceutical (300584.SZ): APIs for some products are actively exploring new processes, including using biofermentation to replace traditional chemical synthesis processes
Gelonghui May 9 丨 Some investors asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does the company have synthetic biotechnology-related technology reserves?” The company replied that the APIs for some of the company's products are actively exploring new processes, including using biological fermentation to replace traditional chemical synthesis processes to further reduce production costs and increase profit margins.
Haichen Pharmaceutical (300584.SZ) announced its 2023 annual results, with net profit of 363.15,600 yuan, an increase of 11.92% year-on-year
According to Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 518 million yuan, a year-on-year decrease of 1.64%; net profit attributable to shareholders of listed companies was 363.15,600 yuan, an increase of 11.92% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 369.653 million yuan, an increase of 17.51% over the previous year; the company plans to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.
Liu Xiaoquan, the majority shareholder of Haichen Pharmaceutical (300584.SZ), plans to reduce holdings by no more than 1.082,700 shares
Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the company's shareholder holding more than 5% of the shares, plans to focus on bidding and big...
Liu Xiaoquan, the main shareholder of Haichen Pharmaceutical (300584.SZ), reduced its shares by 1%
Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the shareholder holding more than 5% of the company's shares, reduced the company's shares by 1...
Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Those holding Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) shares would be relieved that the share price has rebounded 26% in the last thirty days, but it needs to keep going to repair the rec
Haichen Pharmaceutical (300584.SZ): Products suitable for mycoplasma pneumonia are mainly injectable azithromycin
Gelonghui March 6 丨 An investor asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does your company have drugs for mycoplasma pneumonia?” The company replied that the company's products for mycoplasma pneumonia are mainly injectable azithromycin.
Haichen Pharmaceutical (300584.SZ): The main products are injectable landilol hydrochloride, torasemide for injections, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company
Gelonghui March 4 | Haichen Pharmaceutical (300584.SZ) said on the investor interactive platform that the company's main products, such as injectable landilol hydrochloride, injectable torasemide, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company. Among them, injectable landiolol hydrochloride is the exclusive first imitation in China. At the end of 2023, it once again entered the national medical insurance catalogue with a simple contract renewal method; rivaroxaban tablets and injectable tigecycline were selected for centralized drug procurement nationwide. Pharmaceutical R&D innovation has the characteristics of difficulty, long cycle time, and high investment. In the future, the company will integrate clinical needs, its own R&D capabilities, and market conditions
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 25% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) share price has dived 25% in the last thirty days, prolonging recent pain. Instead of being rewarded, s
Haichen Pharmaceutical (300584.SZ) obtained the high-tech enterprise certificate
Gelonghui, January 16, 丨 Haichen Pharmaceutical (300584.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. The date of issue is November 6, 2023. The certificate number is GR202332007846, and the qualification is valid for three years.
Haichen Pharmaceutical (300584.SZ): Landilol hydrochloride for injection passed generic drug consistency evaluation
Gelonghui, December 1丨Haichen Pharmaceutical (300584.SZ) announced that recently, the company received the “Drug Supplement Application Approval Notice” for injectable landilol hydrochloride approved and issued by the State Drug Administration. The product passed the generic drug quality and efficacy consistency evaluation. Injectable landilol hydrochloride is a novel ultra-short-acting adrenaline beta blocker. This type of drug plays an important and irreplaceable role in the treatment of tachyarrhythmia due to its rapid action, rapid metabolism, and rapid beta-blocking effect after discontinuation of the drug. Landiolol hydrochloride for injection is Europe's “2020 ESC/EACTS heart
Haichen Pharmaceutical (300584.SZ): Net profit of 2,947,500 yuan in the third quarter increased by 24.84% year-on-year
Glonghui, October 26丨Haichen Pharmaceutical (300584.SZ) announced its report for the third quarter of 2023. Operating revenue for the reporting period was 116 million yuan, up 4.27% year on year; net profit attributable to shareholders of listed companies was 2.947,500 yuan, up 24.84% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2,585.95 million yuan, up 10.98% year on year; basic earnings per share were 0.0246 yuan.
Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Touches CN¥3.3b Market Cap
Key Insights Nanjing Hicin Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 52% of the company Using data from company's
Haichen Pharmaceutical (300584.SZ): Controlling shareholders, actual controllers, and directors and supervisors promise not to reduce their holdings of the company's shares
Glonghui, September 14, 丨 Haichen Pharmaceutical (300584.SZ) announced that it has recently received a “Letter of Commitment not to reduce company shares within the next six months” from the company's controlling shareholder, actual controller, Mr. Cao Yuping, Ms. Jiang Xiaoqun, and other directors and supervisors holding the company's shares (Supervisor Ms. Luo Yan, Deputy General Manager Mr. Liu Weicheng). The company's controlling shareholders, actual controllers, and other directors and supervisors holding the company's shares voluntarily promise not to reduce their holdings within six months from signing the letter of commitment (that is, September 14, 2023 to March 13, 2024) Shares , including that portion of the commitment period
Haichen Pharmaceutical (300584.SZ) released first-half results, net profit of 19.474,900 yuan, an increase of 9.89%
Haichen Pharmaceutical (300584.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Should Weakness in Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 17% over the past three months, it is easy to disregard Nanjing Hicin Pharmaceutical (SZSE:300584). However, stock prices are usually driven by a company's financials over the lo
Is Now The Time To Put Nanjing Hicin Pharmaceutical (SZSE:300584) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investment
Insiders Were the Key Beneficiaries as Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Market Cap Rises to CN¥3.9b
To get a sense of who is truly in control of Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584), it is important to understand the ownership structure of the business. And the group that holds the
Is Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Nanjing Hicin Pharmaceutical's (SZSE:300584) stock is up by a considerable 33% over the past month. Given the company's impressive performance, we decided to study its financial indicators more clos
The 59% Return Delivered to Nanjing Hicin Pharmaceutical's (SZSE:300584) Shareholders Actually Lagged YoY Earnings Growth
While Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 14% in the last
What Is The Ownership Structure Like For Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584)?
Every investor in Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usual
Analysis
Price Target
No Data
